0597-0182 : Glyxambi Oral Tablet, Film Coated


NDC: 0597-0182
Labeler: Boehringer Ingelheim Pharmaceuticals, Inc.
Product Type: Human Prescription Drug
Drug Name:  Glyxambi
Dosage Form: Oral Tablet, Film Coated
Application #: NDA206073
Rev. Date: 


Appearance:


Markings: 10;5
Shapes:  Triangle (3 sides)
Colors:  Yellow
Size (mm): 8
Segments: * 1

* Segments = the number of equally sized pieces which the pill can be broken into. In this case, a value of 1 indicates a solid pill with no score lines.

NDC Package Codes:

  • 0597-0182-03: 30 TABLET, FILM COATED IN 1 BOTTLE (0597‑0182‑03)
  • 0597-0182-07: 1 BOTTLE IN 1 CARTON (0597‑0182‑07) > 7 TABLET, FILM COATED IN 1 BOTTLE
  • 0597-0182-10: 1000 TABLET, FILM COATED IN 1 BOTTLE (0597‑0182‑10)
  • 0597-0182-30: 30 TABLET, FILM COATED IN 1 BOTTLE (0597‑0182‑30)
  • 0597-0182-39: 30 BLISTER PACK IN 1 CARTON (0597‑0182‑39) > 1 TABLET, FILM COATED IN 1 BLISTER PACK
  • 0597-0182-70: 7 BLISTER PACK IN 1 CARTON (0597‑0182‑70) > 1 TABLET, FILM COATED IN 1 BLISTER PACK
  • 0597-0182-90: 90 TABLET, FILM COATED IN 1 BOTTLE (0597‑0182‑90)

Active Ingredients:

  • Empagliflozin
  • Linagliptin

Dosage Strength:

  • 10 mg
  • 5 mg

Inactive Ingredients:

  • Mannitol
  • Copovidone
  • Crospovidone
  • Titanium Dioxide
  • Talc
  • Starch, Corn
  • Hypromelloses
  • Polyethylene Glycols
  • Magnesium Stearate
  • Ferric Oxide Yellow

Pharmaceutical Classes:

  • Dipeptidyl Peptidase 4 Inhibitor [EPC]
  • Dipeptidyl Peptidase 4 Inhibitors [MoA]
  • Sodium-Glucose Cotransporter 2 Inhibitor [EPC]
  • Sodium-Glucose Transporter 2 Inhibitors [MoA]

Related Products:

Based on records with the same trade name.
  • 0597-0164 Glyxambi Oral Tablet, Film Coated by Boehringer Ingelheim Pharmaceuticals, Inc.
  • 70518-2046 Glyxambi Oral Tablet, Film Coated by Remedyrepack Inc.

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 0597-0182 QR Code

< Prev: 0597-0180Next: 0597-0183 >

Related Discussions:

trajenta linagliptin
what is deference between istamet and trajenta and side effects...




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.